SCHEMBL832026

SCHEMBL832026

O=C(Nc1ccc2c(c1)nc1n2CCC1)c1cc2cc(F)ccc2n1CCOCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 7/20 0.44
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 5/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
APP P05067 3/20 0.43
RAB9A P51151 6/20 0.42
ACHE P22303 4/20 0.42
MAPK1 P28482 3/20 0.42
USP2 O75604 3/20 0.42
HTT P42858 1/20 0.42
BACE1 P56817 1/20 0.42
NPC1 O15118 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HSD17B10 Q99714 3/20 0.42
BCHE P06276 2/20 0.41
ECE1 P42892 1/20 0.41
CASP1 P29466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL833715 0.85 RAB9A (0.47) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL832668 0.82 MAPT (0.41) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL829962 0.82 RAB9A (0.50) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL832123 0.82 ALDH1A1 (0.42) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL832828 0.81 APP (0.44) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL832122 0.81 MEN1 (0.41) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL840177 0.81 APP (0.49) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL831297 0.79 MAPT (0.46) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL831540 0.79 LMNA (0.45) TP53LMNAMAPTALDH1A1KDM4E
SCHEMBL830392 0.75 ALDH1A1 (0.48) TP53LMNAMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288376-B2 Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use SANOFI (FR) 2012-10-16 US disclosed
US-20120122852-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
US-8143248-B2 Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
EP-1987010-B1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2010-04-07 EP disclosed
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122852-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE CYP3A5, CYP2C8, CYP3A43 TP53 3698/4885LMNA 2690/4885MAPT 3000/4885
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE CYP3A5, CYP2C8, PAICS TP53 3752/4885LMNA 2463/4885MAPT 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.